Literature DB >> 21147074

Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease.

Pamela J McMillan1, Sylvia S White, Allyn Franklin, J Lynne Greenup, James B Leverenz, Murray A Raskind, Patricia Szot.   

Abstract

In Parkinson's disease (PD), there is a significant loss of noradrenergic neurons in the locus coeruleus (LC) in addition to the loss of dopaminergic neurons in the substantia nigra (SN). The goal of this study was to determine if the surviving LC noradrenergic neurons in PD demonstrate compensatory changes in response to the neuronal loss, as observed in Alzheimer's disease (AD). Tyrosine hydroxylase (TH) and dopamine β-hydroxylase (DBH) mRNA expression in postmortem LC tissue of control and age-matched PD subjects demonstrated a significant reduction in the number of noradrenergic neurons in the LC of PD subjects. TH mRNA expression/neuron did not differ between control and PD subjects, but DBH mRNA expression/neuron was significantly elevated in PD subjects compared to control. This increase in DBH mRNA expression in PD subjects is not a response to neuronal loss because the amount of DBH mRNA expression/neuron in AD subjects was not significantly different from control. Norepinephrine transporter (NET) binding site concentration in the LC of PD subjects was significantly reduced over the cell body region as well as the peri-LC dendritic zone. In PD subjects, the loss of dendrites from surviving noradrenergic neurons was also apparent with TH-immunoreactivity (IR). This loss of LC dendritic innervation in PD subjects as measured by TH-IR was not due to LC neuronal loss because TH-IR in AD subjects was robust, despite a similar loss of LC neurons. These data suggest that there is a differential response of the noradrenergic nervous system in PD compared to AD in response to the loss of LC neurons. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21147074      PMCID: PMC3038670          DOI: 10.1016/j.brainres.2010.12.015

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  88 in total

1.  Effects of long-term desipramine administration on noradrenergic neurotransmission: electrophysiological studies in the rat brain.

Authors:  D Lacroix; P Blier; O Curet; C de Montigny
Journal:  J Pharmacol Exp Ther       Date:  1991-06       Impact factor: 4.030

2.  Decreased tyrosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson's disease: an in situ hybridization study.

Authors:  F Javoy-Agid; E C Hirsch; S Dumas; C Duyckaerts; J Mallet; Y Agid
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

3.  Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression.

Authors:  V Chan-Palay; E Asan
Journal:  J Comp Neurol       Date:  1989-09-15       Impact factor: 3.215

4.  Isolation and characterization of the human tyrosine hydroxylase gene: identification of 5' alternative splice sites responsible for multiple mRNAs.

Authors:  K L O'Malley; M J Anhalt; B M Martin; J R Kelsoe; S L Winfield; E I Ginns
Journal:  Biochemistry       Date:  1987-11-03       Impact factor: 3.162

5.  Biochemical pathophysiology of Parkinson's disease.

Authors:  O Hornykiewicz; S J Kish
Journal:  Adv Neurol       Date:  1987

6.  Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease.

Authors:  J T Turkka; K K Juujärvi; V V Myllylä
Journal:  Eur Neurol       Date:  1987       Impact factor: 1.710

7.  Human dopamine beta-hydroxylase gene: two mRNA types having different 3'-terminal regions are produced through alternative polyadenylation.

Authors:  K Kobayashi; Y Kurosawa; K Fujita; T Nagatsu
Journal:  Nucleic Acids Res       Date:  1989-02-11       Impact factor: 16.971

8.  A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease.

Authors:  K J Reinikainen; L Paljärvi; M Huuskonen; H Soininen; M Laakso; P J Riekkinen
Journal:  J Neurol Sci       Date:  1988-03       Impact factor: 3.181

9.  Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease.

Authors:  A M Palmer; G K Wilcock; M M Esiri; P T Francis; D M Bowen
Journal:  Brain Res       Date:  1987-01-20       Impact factor: 3.252

Review 10.  Neuropathology of the substantia nigra.

Authors:  W R Gibb
Journal:  Eur Neurol       Date:  1991       Impact factor: 1.710

View more
  37 in total

1.  Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease.

Authors:  Chenyou Sun; Xiaoming Ou; Jerry M Farley; Craig Stockmeier; Steven Bigler; Roberta Diaz Brinton; Jun Ming Wang
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

2.  Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease.

Authors:  Maja Mustapic; Paola Presecki; Nela Pivac; Ninoslav Mimica; Patrick R Hof; Goran Simic; Vera Folnegovic-Smalc; Dorotea Muck-Seler
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-02-13       Impact factor: 5.067

3.  Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.

Authors:  Mary Gannon; Qin Wang
Journal:  Brain Res       Date:  2018-01-04       Impact factor: 3.252

4.  Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.

Authors:  Christopher J Barnum; Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Stefanie Tignor; Anna Klioueva; Hannah Walters; Christopher Bishop
Journal:  Pharmacol Biochem Behav       Date:  2011-09-25       Impact factor: 3.533

5.  Lesioning noradrenergic neurons of the locus coeruleus in C57Bl/6 mice with unilateral 6-hydroxydopamine injection, to assess molecular, electrophysiological and biochemical changes in noradrenergic signaling.

Authors:  P Szot; L Knight; A Franklin; C Sikkema; S Foster; C W Wilkinson; S S White; M A Raskind
Journal:  Neuroscience       Date:  2012-04-25       Impact factor: 3.590

6.  Depressive-like behavior observed with a minimal loss of locus coeruleus (LC) neurons following administration of 6-hydroxydopamine is associated with electrophysiological changes and reversed with precursors of norepinephrine.

Authors:  Patricia Szot; Allyn Franklin; Cristina Miguelez; Yangqing Wang; Igor Vidaurrazaga; Luisa Ugedo; Carl Sikkema; Charles W Wilkinson; Murray A Raskind
Journal:  Neuropharmacology       Date:  2015-09-08       Impact factor: 5.250

Review 7.  Evidence for a specialized role of the locus coeruleus noradrenergic system in cortical circuitries and behavioral operations.

Authors:  Daniel J Chandler
Journal:  Brain Res       Date:  2015-11-25       Impact factor: 3.252

8.  Identification and distribution of projections from monoaminergic and cholinergic nuclei to functionally differentiated subregions of prefrontal cortex.

Authors:  Daniel J Chandler; Carolyn S Lamperski; Barry D Waterhouse
Journal:  Brain Res       Date:  2013-05-07       Impact factor: 3.252

Review 9.  Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase.

Authors:  Medha Priyadarshini; Mohammad A Kamal; Nigel H Greig; Marcella Reale; Adel M Abuzenadah; Adeel G A Chaudhary; Ghazi A Damanhouri
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-06-01       Impact factor: 4.388

Review 10.  Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease.

Authors:  David Weinshenker
Journal:  Trends Neurosci       Date:  2018-02-20       Impact factor: 13.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.